New treatment reduces pathogenic IgG while preserving B‑cell function
News
Nxera partner gains acceptance for NBI‑1117567
Phase 2 study to assess muscarinic M1 agonist in Alzheimer’s cognition
Jemperli accepted for priority review by US FDA
sBLA covers dMMR/MSI‑H stage II–III rectal cancer
Carterra supports AI‑designed protein study with HT-SPR platforms
Anthropic, twist and Adaptyv validate 1,320 binders across 15 targets
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
Designation supports rapid development of pan‑RAS molecular glue
Avulux gains FDA authorisation for migraine light‑sensitivity lens
New device classification created for precision optical filter
Leqembi Iqlik launches in US for early Alzheimer’s
Autoinjector offers at‑home dosing from start of treatment
Lundbeck gains EU orphan status for anti‑ACTH antibody
European ruling supports development in rare endocrine disorders
AC Immune reports positive phase 1 data for ACI‑19764
Early results show safety, CSF penetration and PK clarity
VarmX begins global phase 3 trial for VMX C001
First participant enrolled in EquilibriX S study
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
Study shows reversible switch for targeted cytokine delivery
MHRA sets out position on microbiome‑based medicinal products
Agency clarifies UK pathway for emerging therapies
US FDA accepts Teva’s new drug application for ecopipam
Priority review granted for first‑in‑class Tourette therapy
NICE backs Axhidrox for severe underarm sweating
First guidance for a licensed hyperhidrosis treatment
Alzecure completes transaction with Lilly
Company receives USD 10 million upfront
